Phase 2 Psoriasis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are 18 years old or older, but younger than 80 years old
- You have been diagnosed with plaque psoriasis for more than 6 months
- Your psoriasis covers at least 10% of your body surface area, has a severity score of 12 or higher on the PASI scale, and rates at least 3 out of 5 on a doctor's overall assessment scale (confirm with trial site for exact scoring details)
- Your doctor has determined that you need a full-body (systemic) treatment or light therapy for your psoriasis
- If you are a woman who could become pregnant, you must have a negative pregnancy test before joining
Who may not be able to join:
- You have a type of psoriasis other than plaque psoriasis, such as guttate, erythrodermic, or pustular psoriasis, or psoriasis caused by a medication
- You have a significant history of, or currently have, a serious condition affecting your metabolism, skin, liver, kidneys, blood, lungs, heart, digestive system, nervous system, breathing, hormones, or mental health, or any active infection
- You have a history of cancer, unless it was a non-melanoma skin cancer or a cancer that was fully treated at least 5 years ago with no signs of it coming back
- You have a known allergy or sensitivity to any ingredient in the study drug, ORKA-002
- You are currently breastfeeding or plan to breastfeed during the study
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 781-560-0299
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Proportion of Participants Achieving 100% Reduction in PASI Score at Week 16; Incidence of Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse events (TEAEs) and TEAEs of of Special Interest (TEAESIs)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.